Physician
Martirosian, Richard
Martirosian, Richard was paid $152K by Medicaid between Nov 2020 and May 2024, across 8 billing codes. Its largest line is 87636, Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B — 31% of everything it billed.
33Billing provider infoMARTIROSIAN, RICHARD
MIDDLETOWN, NY 10941
MIDDLETOWN, NY 10941
33aNPI1699208454assigned 04/09/2017
33bProvider typeFamily Medicine Physician
28Total paid$152K
24GClaims1,505
24DCodes billed8
24AFirst – last monthNov 2020 – May 2024
Compared with peers
Next to other Family Medicine Physician providers in New York
Rank by total paid#475 of 2,605
Median peer was paid$10K
This provider vs. median15×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 13 | $1K | |
| 2021 | 473 | $45K | |
| 2022 | 833 | $95K | |
| 2023 | 156 | $9K | |
| 2024incomplete | 30 | $1K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 31% | 359 | 359 | $47K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 29% | 598 | 595 | $43K |
| S9083 | Global fee urgent care centers | 24% | 248 | 246 | $37K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 13% | 197 | 196 | $20K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 25 | 25 | $2K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 38 | 38 | $1K |
| 87634 | <1% | 15 | 15 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 25 | 25 | $550.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.